TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that co-founder and CEO Adi Mor, PhD, will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 11, 2025, at the Sofitel Hotel in New York City. The... Read More

Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025 New Clinical Data... Read More

Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks New Clinical Data Provides Insights on Nebokitug’s Direct Macrophage-Mediated Mechanisms that Are Key to PSC Disease Progression All Three Presentations Have Been Designated as Posters of Distinction TEL AVIV, Israel and WASHINGTON, Nov. 06, 2025 (GLOBE... Read More

TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation... Read More

Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program Phase 2 SPRING Trial Data Highlighting Nebokitug’s Unique Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in PSC Featured at Multiple Major Scientific Meetings FDA and Chemomab Align on CMC and Non-Clinical Toxicology Regulatory Path Forward for Nebokitug Cash Runway through End... Read More

SPRING Trial Data Presented at BSG Live’25 Confirms the Clinical Potential of Nebokitug as a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 Treatment with Nebokitug Is Well-Tolerated and Associated with Substantial Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of PSC Disease Progression TEL AVIV, Israel and GLASGOW, United Kingdom, June 30, 2025 (GLOBE... Read More

Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners Continue TEL AVIV, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . , (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with... Read More

New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041 Further Expands Protections Provided by Nebokitug’s Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and Additional Key Territories TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd .,... Read More

Reported Positive 48-Week Data from SPRING Trial- Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial These Major Milestones Support the Advancement of Nebokitug to Phase 3... Read More

SPRING Trial Data Presented at Digestive Disease Week ® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Progression Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3 TEL AVIV, Israel and SAN DIEGO,... Read More

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Further Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Other Fibro-Inflammatory Conditions Second EASL 2025 Poster Reports that Pharmacokinetic and Pharmacodynamic Data from the Phase... Read More

TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd . , (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including... Read More

David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial in PSC, Assumes Chief Development Officer Role TEL AVIV, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd ., (Nasdaq: CMMB), a clinical stage... Read More

Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in continued improvements across key biomarkers of liver injury, inflammation... Read More

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation that further confirms the... Read More

Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC) Achieved Alignment with FDA on Clear and Efficient Pathway to Potential Regulatory Approval for the Treatment of PSC with No Liver Biopsies or Confirmatory Studies Needed; Nebokitug Positioned to Potentially Become the First FDA-Approved Treatment for PSC On Track for Releasing... Read More

Single Positive Phase 3 Trial Designed to Support Full Regulatory Approval, For the First Time Providing Regulatory Clarity in PSC and Positioning Nebokitug to Potentially Become the First FDA-Approved Treatment for PSC No Liver Biopsies or Additional Confirmatory Studies Required—Phase 3 Trial Endpoint Is Based on Well-Characterized Clinical Events Associated with PSC Disease Progression Derisked Phase 3 Program Leverages... Read More

TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual... Read More

Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts” TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in... Read More

Clinical Data from Phase 2 SPRING Trial Shows that CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis TEL AVIV, Israel, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need,... Read More

FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter 2024 to Discuss the Design of a CM-101 Accelerated Approval Phase 3 Trial in Primary Sclerosing Cholangitis (PSC) Cash Runway Extended to Early 2026; Continuing Discussions with Potential Strategic Partners; Preparations Underway to Advance CM-101 to Phase 3 in Late 2025 TEL AVIV, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB),... Read More

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am... Read More

TEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its late breaking abstract discussing the results of the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the... Read More

TEL AVIV, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that senior management will participate in two upcoming investor conferences. Chemomab management will meet with investors at the Third Annual ROTH Healthcare Opportunities... Read More

TEL AVIV, Israel, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver corporate presentations at the H.C. Wainwright 26th Annual Global Investment Conference and at the HBM Biopharma Summit 2024... Read More

Reported Positive Phase 2 Results Demonstrating Safety and Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC) Establishes Clinical Proof-of-Concept for Disease-Modifying Potential of CM-101 and Provides Foundation for Advancing to PSC Phase 3 Pivotal Trial Completed PIPE Financing Including Major New and Existing Investors that Extends Cash Runway... Read More

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am... Read More

HBM Healthcare Investments, OrbiMed and Sphera Biotech Master Fund LP Participated in the Financing that Extends Cash Runway Potentially to the Beginning of 2026 Chemomab is Well-Positioned to Achieve Key Clinical Milestones in Q1 2025 While Continuing to Advance Its Discussions with Potential Partners Based on Positive Phase 2 Results TEL AVIV, Israel, July 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq:... Read More

TEL AVIV, Israel, July 26, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab) a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance... Read More

TEL AVIV, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") that is expected to result in gross proceeds of... Read More

First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the... Read More

Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC CM-101 Phase 2 PSC Trial Topline Data Readout Expected Midyear 2024 TEL AVIV, Israel, June 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab),... Read More

Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation New Translational Data Further Confirms CM-101’s Disease Modifying Activity in Primary Sclerosing Cholangitis TEL AVIV, Israel, June 06, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage... Read More

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming scientific presentations at the Gordon Research Conference on Chemotactic Cytokines and at EASL 2024, the Annual Congress of the European Association for the Study of... Read More

On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient Enrollment Six Months Ahead of Schedule New Peer-Reviewed Publications Based on Patient Sample Studies Further Reinforce the Key Role of Chemomab’s Novel CCL24 Target in Both PSC and Systemic Sclerosis PSC Expert Webinar Highlights... Read More

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has been granted an additional... Read More

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the Aegis Virtual Conference on May 7, 2024 at 9:00 am ET. Dr. Mor’s presentation will be webcast... Read More

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the... Read More

Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat... Read More

“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare... Read More

European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis Further Extends Protections Afforded by CM-101 Composition of Matter and Methods and Use Patents That Have Issued in the U.S., Europe, Israel and Related Territories TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a... Read More

Accelerated Phase 2 CM-101 PSC Trial Timeline with Topline 15-Week Data Now Planned for Midyear 2024 and Topline Open Label Data Expected in Late 2024/Early 2025 Cash Runway Extended through End of First Quarter 2025 as a Result of Early Completion of Phase 2 PSC Trial and Effective Financial Management 2023 Achievements Position Chemomab for a Potentially Transformational 2024 TEL AVIV, Israel , March 7, 2024 /PRNewswire/... Read More

TEL AVIV, Israel , March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor will deliver a corporate presentation and participate in investor meetings at the Leerink Partners Global Biopharma Conference , March 11-13, 2024 in Miami,... Read More

CM-101 Phase 2 Trial for the Treatment of Primary Sclerosing Cholangitis (PSC) Has Completed Patient Enrollment with Topline Data Expected Midyear 2024 New CM-101 Patents Granted by Brazil and Israel Provide Additional Protections for Composition of Matter and for Use in Fibrotic Diseases of the Liver, including PSC Further Extend Protections Afforded by Multiple CM-101 Patents that Have Issued in the U.S., Europe , Israel... Read More

TEL AVIV, Israel , Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024 , at 7:00 am Eastern Time... Read More

TEL AVIV, Israel , Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences. Dr. Mor will deliver a... Read More

Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomab's CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC CM-101 Phase 2 PSC Trial Has Completed Patient Enrollment with Topline Data Readout Targeted for Midyear 2024 TEL AVIV, Israel , Jan. 30,... Read More

Expected Topline Data Readout Accelerated to Midyear 2024 Following Early Completion of Patient Enrollment in Phase 2 Primary Sclerosing Cholangitis (PSC) SPRING Trial CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in PSC, Which Often Results in Liver Transplant or Death and Lacks Any FDA-Approved Treatments TEL AVIV, Israel , Jan. 3, 2024 /PRNewswire/ -- Chemomab... Read More

Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension - Study Reveals that CCL24 Activates Endothelial Cells in Specific Ways that Result in SSc-Associated Fibrosis TEL AVIV, Israel , Nov. 16, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on... Read More

CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Has Disease Modifying Potential in this Poorly Treated Condition CM-101's Phase 2 SPRING Trial in PSC is Advancing Towards Completion of Enrollment with Top-line Readout Expected in 2H 2024 TEL AVIV, Israel , Nov. 15, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and... Read More

New Proteomic Analyses of Phase 2a Liver Fibrosis Clinical Data Show Consistent and Significant Improvements in Liver-related Pathology Pathways After Treatment with CM-101 Oral Presentation of Proteomic Analyses in PSC Patients Provides Further Evidence that CCL24 Is a Key Driver of the Inflammatory and Fibrotic Processes Underlying PSC and Other Disorders TEL AVIV, Israel , Nov. 13, 2023 /PRNewswire/ -- Chemomab... Read More

Continued Strong Progress in Advancing CM-101 Phase 2 PSC Trial Towards Completion of Enrollment--On Track for Topline Readout in Second Half of 2024 Reiterates Guidance that Cash Reserves Are Sufficient to Fund the Company Through the End of 2024, with Decreasing Quarterly Cash Burn Expected to Continue TEL AVIV, Israel , Nov. 9, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage... Read More

Chemomab's ADSs Will Continue to Trade on the Nasdaq Capital Market TEL AVIV, Israel , Nov. 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab", or the "Company"), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today disclosed that the Company received notice ("Notice") from the Nasdaq... Read More

TEL AVIV, Israel , Oct. 30, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will release its third quarter 2023 financial results and a business update on November 9, 2023 at 8:00 am Eastern Time . Investors who would like to discuss the... Read More

TEL AVIV, Israel , Oct. 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will present at major U.S. scientific conferences in November, including an oral presentation on primary sclerosing cholangitis and a... Read More

CM-101's Unique Dual Anti-Fibrotic and Anti-Inflammatory Activity Supports Its Disease Modifying Potential in Primary Sclerosing Cholangitis (PSC) CM-101 Phase 2 SPRING Trial in PSC is Advancing Towards Completion of Enrollment with Topline Readout Currently Targeted in Second Half of 2024 TEL AVIV, Israel , Sept. 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology... Read More

Virtual presentation to be available starting on September 11, 2023 , at 7 AM Eastern Time TEL AVIV, Israel , Aug. 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced that Adi Mor, PhD, co-founder, Chief Executive Officer and Chief Scientific... Read More

On Track to Achieve CM-101 PSC Phase 2 Readout Expected in 2H2024 Extended Estimated Cash Runway Through PSC Readout and 2024 Year-End Reported Positive Secondary Analysis of Data from CM-101 Phase 2 Liver Fibrosis Trial Successfully Implemented Senior Management Changes and Cost Saving Measures4 Published New Peer-Reviewed Articles and Presented Scientific Posters at European Medical Meetings Highlighting Therapeutic... Read More

Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC TEL AVIV, Israel , June 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced the publication of a... Read More

New Proteomics Data Further Confirms the Relationship between CM-101's CCL24 Target and Primary Sclerosing Cholangitis (PSC) Disease Pathways Provides Further Evidence that CM-101 Interrupts Fibrotic and Inflammatory Disease Processes Driven by Elevated Levels of CCL24 TEL AVIV, Israel and VIENNA , June 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company... Read More

Treatment with CM-101 Improves Additional Biomarkers of Fibrosis and Inflammation, Reinforcing and Extending Initial Study Results Provides New Insights into CM-101 Activity in NASH Patients at Greater Risk of Progressive Disease, Providing Further Support for CM-101's Direct Anti-inflammatory and Anti-fibrotic Dual Mode of Action Demonstrates Improvements in Key Biomarkers Associated with Other Fibrotic Liver Diseases... Read More

Adi Mor, PhD, Co-founder, Board Director and Chief Scientific Officer, Reappointed to CEO Role Sigal Fattal, Vice President Finance, Reappointed as CFO On Track for PSC Phase 2 Topline Data Readout in Latter Part of 2024 Implementing Further Reorganization and Efficiency Measures Intended to Extend Cash Runway to End of 2024, After Expected PSC Phase 2 Topline Data Readout Nissim Darvish, MD, PhD, Appointed Chairman of the... Read More

New Patient Data Further Implicates CCL24 in Fibrotic Disease Pathology and Prognosis and Supports Rationale for the Role of Chemomab's CCL24-Neutralizing Antibody CM-101 in Systemic Sclerosis and Other Fibro-inflammatory Diseases MILAN and TEL AVIV, Israel , June 2, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of... Read More

TEL AVIV, Israel , May 24, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced upcoming CM-101 data presentations at major European scientific conferences in June 2023 , including EULAR 23 , the European Congress of... Read More

Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers Received FDA Clearance for CM-101 Systemic Sclerosis IND—Phase 2 Trial Expected to Open Mid-year Advancing Phase 2 PSC Trial and Enrolling Patients in Higher Dose Cohort Extending Estimated Cash Runway Through First Half of 2024 Company to Host... Read More

TEL AVIV, Israel , April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2 – May 4, 2023 . Chemomab management will present a corporate... Read More

TEL AVIV, Israel , April 19, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in a number of scientific conferences in April and May. British Society for Rheumatology Annual Conference –... Read More

This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023 TEL AVIV, Israel , April 12, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its... Read More

TEL AVIV, Israel , March 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will provide a Corporate Update on Monday, April 17, 2023 , at 8:00 am Eastern Time . This event replaces the webcast and call... Read More

TEL AVIV, Israel , March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023 , at 8:00... Read More

TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33 rd Annual Healthcare Conference... Read More

ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis TEL AVIV, Israel , Feb. 21, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with... Read More

CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments TEL AVIV, Israel , Jan. 3, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need,... Read More

Clean Safety Review Supports Addition of Higher Dose Cohort into the Trial TEL AVIV, Israel , Dec. 21, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that an independent Data Monitoring Committee (DMC) has completed a... Read More

TEL AVIV, Israel , Nov. 30, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the appointment of Mitchell L. Jones , MD, PhD, as Vice President of Corporate Development & Strategy. Dr. Jones brings Chemomab more than... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time . During the event, Chemomab's... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November. AASLD - The Liver Meeting ® 2022 Date: November 4-8, 2022 Venue: Walter E. Washington Convention Center,... Read More

Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2022 and provided a corporate update.... Read More

Appoints Ilan Vaknin, PhD, as Vice President of Research & Development and Christina Crater , MD, as Vice President of Clinical Development Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin , PhD, MBA, as Vice... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time . During the event, Chemomab's... Read More

Data Presented at 2022 EASL International Liver Conference TM and First International Extracellular Matrix Pharmacology Congress Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported on two recent presentations at important scientific... Read More

Ms. Quigley's Broad Biotechnology Industry Experience Encompasses Leadership Positions in Executive Management, Operations and Legal Affairs Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Jill M. Quigley , JD, has been appointed to... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that the company will participate in a number of investor and scientific conferences in June 2022 . JMP Securities Life Sciences Conference: Date: Thursday, June 16 , 2022 Venue : Lotte... Read More

Poster Presentation of Reverse Translational Study Data Using Patient Samples Supports Role of CCL24 as a Therapeutic Target for Systemic Sclerosis Chemomab's CCL24-Neutralizing Antibody CM-101 Is Expected to Enter a Phase 2 Trial in Systemic Sclerosis in Late 2022 Chemomab Therapeutics, Ltd . (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022. HC Wainwright Global Investment... Read More

Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2022 and provided a corporate update. "During the... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its first quarter 2022 financial results and provide a business... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald... Read More

Translational Study Data Presented at 7 th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum Levels in Patients were Correlated with Greater Disease Activity and Worse Prognosis Chemomab Also Presented Data from Multiple Preclinical Studies at the... Read More

Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the fourth quarter and year ended December 31, 2021 , and... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its fourth quarter and full year 2021 financial results and provide a business update on Wednesday, March 9, 2022 . The company will host a conference call and... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022 , at 9:00 am ET . To access the event: click... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today named Jack Lawler Vice President of Global Clinical Development Operations. Mr. Lawler, who is... Read More

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that senior management will participate in the LifeSci Partners 11 th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that, as planned and announced earlier this year, CEO Dale R. Pfost , PhD will assume the additional role of Chairman, subject to the approval of Chemomab's shareholders, as is required... Read More

Chemomab Therapeutics Ltd . (NASDAQ: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that David M. Weiner , MD has been named Interim Chief Medical Officer, effective immediately. This position will be in a part-time capacity. Dr. Weiner is replacing Dr. Arnon Aharon , who has... Read More

Chemomab Therapeutics, Ltd . (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2021 , and provided a corporate update. Recent Highlights and Upcoming Events Presenting a poster at The Liver Meeting ®... Read More

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced a poster presentation at The Liver Meeting ® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12-15, 2021 . The preclinical poster,... Read More

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced it will host a live presentation and participate in 1-on-1 investor meetings at Stifel's 2021 Virtual Healthcare Conference. Presentation details: Date: November 15, 2021 Time: 8:00 AM ET... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that Donald R. Marvin has been named Chief Financial Officer, Executive Vice President and Chief Operating Officer. Mr. Marvin is a seasoned biotechnology executive with over 35 years of... Read More

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will host a key opinion leader (KOL) live webinar featuring systemic sclerosis (SSc) expert Dr. Dinesh Khanna on Wednesday, November 3, 2021 , at 10:00 am Eastern Time . Dr. Khanna,... Read More

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) ("Chemomab"), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced a research collaboration with Leeds University to further study the role of CCL24 in the vascular damage associated with systemic sclerosis (SSc), a rare rheumatic disease with high morbidity... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for inflammatory and fibrotic diseases with high unmet need, today announced it has appointed Dale R. Pfost , PhD, as Chief Executive Officer (CEO). Dr. Adi Mor , Company co-founder and current CEO, will continue in her role as Chief Scientific Officer (CSO) and remain as a member... Read More

Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the Company will participate in the following upcoming investor conferences in September: Citi 16 th Annual... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Recent Highlights CM-101 Phase 2a SPRING trial in primary sclerosing cholangitis (PSC) continues to enroll... Read More

Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary... Read More

Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced a poster presentation at the International Liver Congress 2021 (EASL), which is being held virtually on June 23-26, 2021 . Dr. Arnon Aharon , Chemomab's CMO, will present the poster entitled : The peri-ductular... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2021 and provided a business update. "This quarter has been truly exciting for Chemomab as we accessed the public markets and began to trade on... Read More

Chemomab Therapeutics Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced that the company's CEO, Dr. Adi Mor will present a corporate update at Oppenheimer's virtual Rare and Orphan Disease Summit on May 21 st , 2021. Webcast link may be accessed here . The presentation will be available... Read More

Chemomab Therapeutics, Ltd . (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is... Read More

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced the appointment of Dr. Alan Moses , Dr. Claude Nicaise , Mr. Joel Maryles , and Mr. Neil Cohen to Chemomab's Board of Directors. Dr. Stephen Squinto will remain Chairman of Chemomab's Board. Dr. Adi Mor and Dr.... Read More